Ketan D. Patel, Ph.D., joined St. John’s University as an Assistant Professor of Pharmaceutical Sciences in September of 2016. He holds a Ph.D. in Pharmaceutics from the Institute of Chemical Technology, Mumbai, India (2013), and a M.Pharm. from Mumbai University, India (2009).
He was awarded All India Council for Technical Education and University Grants Commission Special Assistance Programme fellowships for securing first rank in India on the Graduate Aptitude Test in Engineering in 2007 and the Institute of Chemical Technology Ph.D. entrance exam in 2009. Post completion of his Ph.D., he joined the Department of Pharmaceutical Sciences at Florida A&M University as a postdoctoral fellow on a National Institutes of Health-funded research project on lung cancer.
During his postdoctoral tenure from January of 2014 through June of 2016, he worked on various projects, including targeted nanotherapeutics for lung and breast cancer treatment; overcoming drug resistance in lung cancer; topical formulations for chemoprevention; and psoriasis treatment. He has received a number of oral/poster/travelship awards for presenting his research at various international conferences, including those organized by the American Association of Pharmaceutical Scientists and the Controlled Release Society.
Dr. Patel has authored more than 50 research publications in prestigious, peer-reviewed journals in the area of pharmaceutics, 3D printing, opioid abuse deterrent formulation, pre-exposure prophylaxis of HIV, and cancer nanotechnology. He has five US patents (three received and two pending) on innovative formulation technologies.
Dr. Patel recently received a Melanoma Research Scholar Award from Outrun the Sun, Inc. and a National Institutes of Health grant for his research on development of nanomedicine of Proteolysis Targeting Chimera (PROTAC) for the treatment of metastatic melanoma. Currently, he mentors five doctoral students and two undergraduate students in his laboratory.
Pharmaceutics, Extemporaneous compounding, Biopharmaceutics
A. Tumor targeted nanotherapeutics for the treatment of melanoma and pancreatic cancer B. Solubility and bioavailability enhancement of anti-diabetic and anti-hyperlipidamic class of drugs using liquisolid technique, Hot Melt Extrusion and 3D printing.
IPP 233 INDUSTRIAL PHARM JOURNAL CLUB
PHS 3601 PHARMACEUTICS I FOR PHARMD
PHS 3603 PHARMACEUTICS II FOR PHARM D
PHS 4602 BIOPHA & BASIC PHARMACOKINETIC
Boakye, C. H., Patel, K. D., Doddapaneni, R., Bagde, A., Marepally, S., and Singh, M. (2017). Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. Journal of Controlled Release. vol. 246, pp. 120–132.
Patel, K. D., Doddapaneni, R., Chowdhury, N., Boakye, C. H., Behl, G., and Singh, M. (2016). Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine. vol. 11, pp. 1377–1392.
Patel, K. D., Doddapaneni, R., Sekar, V., Chowdhury, N., and Singh, M. (2016). Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Molecular pharmaceutics. vol. 13, pp. 2049–2058.
Doddapaneni, R., Patel, K. D., Owaid, I. H., and Singh, M. (2016). Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug delivery. vol. 23, pp. 1232–1241.
Doddapaneni, R., Patel, K. D., Chowdhury, N., and Singh, M. (2016). Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Experimental cell research. vol. 346, pp. 65–73.
Lacey, A., Hedrick, E., Li, X., Patel, K. D., Doddapaneni, R., Singh, M., and Safe, S. (2016). Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). Oncotarget. vol. 7, pp. 31257.
Cheriyan, V. T., Muthu, M., Patel, K. D., Sekhar, S., Rajeswaran, W., Larsen, S. D., Polin, L., Levi, E., Singh, M., and Rishi, A. K. (2016). CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget. vol. 7, pp. 73370.
Boakye, C. H., Patel, K. D., Patel, A. R., Faria, H. A., Zucolotto, V., Safe, S., and Singh, M. (2016). Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation. Drug Delivery and Translational Research. vol. 6, pp. 526–539.
Boakye, C. H., Patel, K. D., Doddapaneni, R., Bagde, A., Behl, G., Chowdhury, N., Safe, S., and Singh, M. (2016). Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids and Surfaces B: Biointerfaces. vol. 143, pp. 156–167.
Patel, K. D., Chowdhury, N., Doddapaneni, R., Boakye, C. H., Godugu, C., and Singh, M. (2015). Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of pharmaceutical sciences. vol. 104, pp. 4417–4426.
Boakye, C. H., Patel, K. D., and Singh, M. (2015). Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. International journal of pharmaceutics. vol. 489, pp. 106–116.
Patel, K. D., Patil, A., Mehta, M., Gota, V., and Vavia, P. (2014). Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. International journal of pharmaceutics. vol. 472, pp. 214–223.
Patel, K. D., Patil, A., Mehta, M., Gota, V., and Vavia, P. (2013). Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol®. Journal of biomedical nanotechnology. vol. 9, pp. 1996–2006.